65 year-old Jenny was diagnosed with triple-positive breast cancer in 2017. After completing radiotherapy, chemotherapy and HER 2 targeted therapies, she was enrolled in a NERLYNX® trial program. Click on the image banner above to play the video.
Cath Griffiths has been an oncology nurse for almost 30 years and has extensive experience in managing breast cancer patients who have been taking NERLYNX within trial programs. In this piece, she provides her advice on optimal patient management. Click on the image banner above to play the video.
47-year-old mother-of-two Kate Harper was diagnosed with HER2+ breast cancer in 2017. Following chemotherapy and trastuzumab-based therapy, she has commenced NERLYNX therapy. She has continued working throughout her treatment. Click on the image banner above to play the video.